Special Issue

Artificial Intelligence in Deep Brain Stimulation

Message from the Guest Editors

The use of deep brain stimulation (DBS) for a variety of neurological and psychiatric disorders is one of the most important advances in clinical neuroscience over the past two decades. DBS enables neuroscientists to obtain direct measures of neuronal activities, interrogate the function of neural circuits, and investigate the therapeutic potential of modulating these circuits with unprecedented spatial and temporal precision. This Special Issue of *Biomedicines*, "Artificial Intelligence in Deep Brain Stimulation", will mainly focus on the recent advances in the application of AI in DBS to contextualize the current body of research and discuss potential future directions. We cordially invite authors to submit original research or review articles pertaining to this important and fast-growing field. The goal is to stimulate research and clinical interests in this exciting field of biomedicine with the hope of developing strategies to integrate artificial intelligence for precision neuromodulation therapy.

Guest Editors

Dr. Joshua Wong

Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA

Dr. Jun Yu

Norman Fixel Institute for Neurological Diseases, University of Florida, Gainesville, FL 32608, USA

Deadline for manuscript submissions

closed (15 June 2023)

MDPI

Biomedicines

an Open Access Journal by MDPI

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).